{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T21:02:13Z","timestamp":1772139733691,"version":"3.50.1"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003786","name":"Hangzhou Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003786","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.lungcan.2020.04.031","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T16:10:12Z","timestamp":1588608612000},"page":"370-372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib"],"prefix":"10.1016","volume":"146","author":[{"given":"Yao","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yina","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Junrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2020.04.031_bib0005","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1158\/1078-0432.CCR-13-0318","article-title":"ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer","volume":"19","author":"Gainor","year":"2013","journal-title":"Clin Cancer Res Official J Am Assoc Cancer Res"},{"key":"10.1016\/j.lungcan.2020.04.031_bib0010","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4\u2013ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2020.04.031_bib0015","doi-asserted-by":"crossref","first-page":"100015","DOI":"10.1016\/j.jtocrr.2020.100015","article-title":"Catalog of 5\u2019 Fusion Partners in ALK-positive NSCLC Circa 2020","volume":"1","author":"Ou","year":"2020","journal-title":"Jto Clin Res Reports"},{"key":"10.1016\/j.lungcan.2020.04.031_bib0020","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"New Engl J Med"},{"key":"10.1016\/j.lungcan.2020.04.031_bib0025","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1016\/j.jtho.2018.11.027","article-title":"SRBD1-ALK, a Novel ALK Fusion Gene Identified in an Adenocarcinoma Patient by Next-Generation Sequencing","volume":"14","author":"Hou","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2020.04.031_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15384047.2018.1480282","article-title":"CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib","volume":"19","author":"Du","year":"2018","journal-title":"Cancer Biol Ther"},{"issue":"111","key":"10.1016\/j.lungcan.2020.04.031_bib0035","first-page":"116","article-title":"A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing-Based Circulating Tumor DNA Profiling Exhibits Excellent Response to Crizotinib","volume":"1","author":"PhD","year":"2017","journal-title":"Mayo Clin Proc Innovations Qual Outcomes"},{"key":"10.1016\/j.lungcan.2020.04.031_bib0040","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.jtho.2018.07.008","article-title":"Brief Report: CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small-Cell Lung Cancer","volume":"13","author":"Zhang","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2020.04.031_bib0045","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1158\/1078-0432.CCR-11-3260","article-title":"Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants","volume":"18","author":"Heuckmann","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2020.04.031_bib0050","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00018-015-2117-6","article-title":"Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs","volume":"73","author":"Bayliss","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.lungcan.2020.04.031_bib0055","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3390\/cancers9090118","article-title":"EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients","volume":"9","author":"Sabir","year":"2017","journal-title":"Cancers"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220304013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220304013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:57:00Z","timestamp":1759237020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500220304013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":11,"alternative-id":["S0169500220304013"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.04.031","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.04.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}